BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF, FR:5LB), formerly BioVaxys LLC, is a British Columbia-registered clinical-stage biotechnology company dedicated to improving patient lives with novel immunotherapies based on our DPX™ immune-educating delivery technology platform and our HapTenix© neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. 


https://biovaxys.com/

Therapeutics

Bio Vaxys Technology Corp. announced it raised $249,000 in an initial filing from an offering of $249,000

Company Information

Funding Insights

Related People

Bio Vaxys Technology Corp. announced it raised $249,000 in an initial filing from an offering of $249,000

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Related People

Company Information